Is WAT stock overvalued right now?

Based on our discounted cash flow and relative valuation models, WAT appears to trade above fair value by approximately 77.6%. This suggests the market may be pricing in elevated growth expectations or sentiment premiums.

What is WAT fair value based on current fundamentals?

Our fair value estimate for WAT is $93.52, derived from discounted cash flow, dividend discount, and relative valuation multiples. The estimate assumes a discount rate of 9.0% and terminal growth of 2.5%.

How risky is WAT compared with other stocks?

WAT carries a beta of 1.19 is near market average. Investors should weigh macro exposure against their own risk tolerance.

Is WAT still growing?

Latest trailing metrics show revenue growth of 113.4%. Profit margins are 3.6%.

What do analysts think about WAT?

Analyst consensus target is $442.71, implying 6.1% upside. The street recommendation is "buy".

What could change the investment case for WAT?

Key catalysts include Healthcare sector dynamics, interest rate shifts, and company-specific earnings surprises. Monitor macro risk scores and analyst estimate revisions for early signals.

HealthcareUpdated·Data: Yahoo Finance, SEC EDGAR·Data delayed ~5 min

Deep Dive WAT Deep Value Discount FX Impact result Bull Run

NYQ · Healthcare · Diagnostics & Research

$417.09

+7.08 (+1.73%)

Stock valuation guide Macro risk explained guide

About the Author

Phasakorn Traklang (Peach) — Founder

Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.

Connect on LinkedIn

Investment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC

Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.